Adaptive Biotechnologies (ADPT) Accumulated Expenses (2018 - 2026)

Adaptive Biotechnologies has reported Accumulated Expenses for 9 years, with the latest figure at $6.2 million in Q1 2026.

• Quarterly Accumulated Expenses fell 19.85% year-over-year to $6.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.2 million (down 19.85% YoY) and the FY2025 annual result came in at $7.7 million, down 51.38% from the prior year.
• Accumulated Expenses retreated to $6.2 million in Q1 2026 per ADPT's latest filing, from $7.7 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $15.9 million in Q4 2022 and troughed at $6.2 million in Q1 2026.
• A 5-year average of $10.1 million and a median of $9.8 million in 2022 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses climbed 21.53% in 2024, then sank 51.38% in 2025.
• Over 5 years, Accumulated Expenses stood at $15.9 million in 2022, then slipped by 14.12% to $13.7 million in 2023, then increased by 15.73% to $15.8 million in 2024, then tumbled by 51.38% to $7.7 million in 2025, then slipped by 19.26% to $6.2 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $6.2 million, $7.7 million, and $12.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.